^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Acute Promyelocytic Leukemia |
| Drug: | cytarabine (DNA synthesis inhibitor, DNA-directed DNAP inhibitor) + daunorubicin (Topoisomerase II inhibitor, DNA intercalator) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
APL treatment induction...regimen added...Consolidation: daunorubicin 60 mg/m2 x 3 days + cytarabine 200 mg/m2 x 7 days x 1 cycle, then cytarabine 2 g/m2 (age <50) or 1.5 g/m2 (age 50-60) every 12 h x 5 days + daunorubicin 45 mg/m2 x 3 days x 1 cycle + 5 doses of intrathecal (IT) chemotherapy
